Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Generate Biomedicines, Inc. before investing.

In this article, we go over a few key elements for understanding Generate Biomedicines, Inc.’s stock price such as:

• Generate Biomedicines, Inc.’s current stock price and volume
• Why Generate Biomedicines, Inc.’s stock price changed recently
• Upgrades and downgrades for GENB from analysts
• GENB’s stock price momentum as measured by its relative strength

About Generate Biomedicines, Inc. (GENB)

Before we jump into Generate Biomedicines, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Want to learn more about Generate Biomedicines, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Generate Biomedicines, Inc..

Generate Biomedicines, Inc.’s Stock Price as of Market Close

As of June 02, 2026, 12:45 PM, CST, Generate Biomedicines, Inc.’s stock price was $12.040.

Generate Biomedicines, Inc. is down 7.17% from its previous closing price of $12.970.

During the last market session, Generate Biomedicines, Inc.’s stock traded between $11.950 and $12.970. Currently, there are approximately 64.87 million shares outstanding for Generate Biomedicines, Inc..

Generate Biomedicines, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Generate Biomedicines, Inc. Stock Price History

Generate Biomedicines, Inc.’s (GENB) price is currently down 8.23% so far this month.

During the month of June, Generate Biomedicines, Inc.’s stock price has reached a high of $13.370 and a low of $11.950.

Over the last year, Generate Biomedicines, Inc. has hit prices as high as $16.748 and as low as $11.000.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Generate Biomedicines, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 01, 2026, there were analysts who downgraded Generate Biomedicines, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Generate Biomedicines, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Generate Biomedicines, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Generate Biomedicines, Inc. (GENB) by visiting AAII Stock Evaluator.

Relative Price Strength of Generate Biomedicines, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 01, 2026, Generate Biomedicines, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Generate Biomedicines, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Generate Biomedicines, Inc. Stock Price: Bottom Line

As of June 2, 2026, Generate Biomedicines, Inc.’s stock price is $12.040, which is down 7.17% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Generate Biomedicines, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.